Exelixis Stock News

Cambiar Investors LLC lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.5% during the 3rd quarter, Holdings Channel reports. The firm owned 617,306 shares of the biotechnology companys stock after selling 2,939 shares during the quarter. Cambiar Investors LLCs holdings in Exelixis were worth $13,050,000 as of its most recent filing with the []

It''s been a feast for bulls operating on the daily timeframe, as exel has now gone up 4 of the past 5 days. The post Exelixis Inc (EXEL): Price Now Near $16.56; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .

Oregon Public Employees Retirement Fund cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,649 shares of the biotechnology companys stock after selling 739 shares during the quarter. Oregon Public Employees Retirement Funds holdings []

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axiom Investment Management LLC decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 57.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 36,231 shares of the biotechnology companys stock after selling 48,349 shares during the period. Axiom Investment Management LLCs holdings in Exelixis were worth $766,000 as of its most recent filing with the []

Since the last earnings report, shares of Exelixis declined over 20% because of a slight adjustment of the FJ outlook. Total revenue is still likely to grow 35% in FJ 2021 at the midpoint of the updat

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 17,236 shares of Exelixis stock in a transaction on Wednesday, November 24th. The shares were sold at an average price of $17.25, for a total transaction of $297,321.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this []

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 17,236 shares of Exelixis stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $17.25, for a total transaction of $297,321.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through []

Retail Logistics Market has recently added by Qurate Research to its vast repository. This intelligence report includes investigations based on Current scenarios, Historical records, and future predictions. Report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications,

Louisiana State Employees Retirement System cut its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 80,400 shares of the biotechnology companys stock after selling 900 shares during the quarter. Louisiana State Employees Retirement Systems holdings in Exelixis were worth $1,700,000 at the end of the most recent []

Exelixis, Inc. (NASDAQ:EXEL) Equities research analysts at Piper Sandler issued their FY2023 earnings per share estimates for shares of Exelixis in a report issued on Thursday, November 18th. Piper Sandler analyst D. Kim expects that the biotechnology company will post earnings of $1.06 per share for the year. Piper Sandler currently has a Overweight []

Mariner LLC trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL) by 4.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,828 shares of the biotechnology companys stock after selling 808 shares during the period. Mariner LLCs holdings in Exelixis were worth []

Exelixis intends to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in early 2022 following the final overall survival analysis ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 20, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from

Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or followi